Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
Follow ADVB
Advanced Biomed Inc. (ADVB) P/E ratio
As of 16 October 2026, Advanced Biomed Inc. (ADVB) trades at a P/E ratio of 0.8×. Over the past ten years it has ranged from 0.0× (December 2025) to 3.7× (July 2026); the current reading is higher than 51% of that period. That is below the Diagnostics & Research industry median of 35.6× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.9× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| NOTVQ Inotiv, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| PMD Psychemedics Corporation compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| ISPC iSpecimen Inc. compare | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| ADVB Advanced Biomed Inc. | 0.8× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)